The Long Term Effective Antiviral Therapy In Asym Ptomatic Chronic Hepatitis B Virus Carrier

Objective:To evaluate the long term effect and safety of entecavir for the treatment of asymptomatic chronic hepatitis B virus carrier.Methods:89 cases of chronic hepatitis B virus infection were divided into two groups:the group of asymptomatic chronic hepatitis B virus carriers,47 cases,and the group of chronic hepatitis B,42 cases.All of the 89 cases were given 0.5mg ETV orally once a day for 192 weeks.To observe the difference between two groups of patients in each observation node(12 weeks,24 weeks,48 weeks,96 weeks,144 weeks,192 weeks)of virological response rate,serological response rate,and biochemical breakthrough rate.Side effects of entecavir and the incidence of Hepatitis B virus related adverse events were observed regularly.Results:HBV DNA contents:there was no statistically significant difference between the two groups in the observed node(P>0.05).Virological response rates,in the two groups were 89.4%and 85.7%at 12 weeks,91.5%and 92.9%at 24 weeks,80.9%and 88.1%at 48 weeks,72.3%and 81.0%at 96 weeks,83.0%and 73.8%at 144 weeks,89.4%and 85.7%at 192 weeks.There was no statistical significant difference between the two groups(P>0.05).HBsAg Contents:there were statistical significant differences in HBsAg content(P<0.05)between the two groups in the study of HBsAg in week 12,24 and 48(P<0.05),and there was no statistical significant difference in the contents of HBsAg in the week 96,144 and 192(P>0.05).Serological response,hepatitis B e Antigen response rates in the group of chronic hepatitis B virus carriers and the group of chronic hepatitis B were 4.3%and 4.3%at 12 weeks,4.3%and 11.9%at 24 weeks,10.6%and 19.0%at 48 weeks,14.9%and 23.8%at 96 weeks,21.3%and 35.7%at 144 weeks,29.8%and 38.1%at 192 weeks.There was no statistical significant difference between the two groups(P>0.05).There was no HBsAg negative and seroconversion tested in both groups during 48 weeks of treatment.Biochemistry breakthrough rates in the group of chronic hepatitis B virus carriers and the group of chronic hepatitis B were 2.1%and 2.4%at 12 weeks,both 0 at 24 weeks,0 and 7.1%at 48 weeks,4.3%and 4.8%at 96 weeks,2.1%and 4.8%at 144 weeks,2.1%and 11.9%at 192 weeks.There was no statistical significant difference between the two groups(P>0.05).No liver cirrhosis happened in both groups.One patient in the group of chronic hepatitis B had hepatocellular carcinoma at 48 weeks.There was no side effects of entecavir observed in both groups.Conclusion:The long term antiviral therapy with entecavir in chronic hepatitis B virus carriers was effective,safe.